In recent years, GLP-1 receptor agonist drugs have gained strong traction in both medical and media discussions, especially for their role in weight loss and in the treatment of type 2 diabetes. Their widespread use has reshaped expectations among patients and professionals, shifting the focus from a lifestyle-only approach to obesity toward more structured therapeutic strategies.
The picture, however, is complex. On one hand, significant clinical results are emerging, with notable reductions in body weight and improvements in glycemic control. On the other, several aspects that are often simplified or overlooked are becoming increasingly evident: the management of side effects, the quality of weight loss, and the long-term sustainability of the therapy.
Understanding what GLP-1 agonists are and how they work is therefore only the first step. The key point lies in how these drugs fit into a real-world pathway, made up of adaptation, monitoring, and continuity, where effectiveness must coexist with tolerability and long-term results maintenance.
GLP-1 (glucagon-like peptide-1) is a hormone naturally produced in the small intestine after food intake. It belongs to the incretin family, molecules that help the body manage nutrients more efficiently, especially blood glucose levels and body weight. Its role goes beyond a single function: it coordinates multiple metabolic signals involving the pancreas, digestive system, and central nervous system.
Based on this physiological mechanism, GLP-1 receptor agonist drugs have been developed—molecules designed to mimic and enhance the action of the natural hormone. Unlike endogenous GLP-1, which is degraded within minutes, these drugs have a much longer duration of action and allow for more stable control over time.
Their effects operate on multiple levels:
This combined action explains why GLP-1 drugs are now used both in the treatment of type 2 diabetes and in weight management. The outcome is not tied to a single mechanism, but to a broader regulation of energy balance, affecting how the body takes in, uses, and stores energy.
It quickly becomes clear that this is not an isolated effect, but a complex modulation of metabolism, which explains why these drugs are changing the way obesity and diabetes are managed.
To understand why these drugs have had such a strong impact in clinical practice, it is necessary to look at how they act simultaneously on multiple mechanisms, modifying the metabolic response.
As mentioned earlier, GLP-1 receptor agonist drugs work by significantly reducing appetite and increasing the feeling of fullness. This effect is not simply due to “forcing” a diet, but rather to a modification of the signals that regulate hunger, making it easier to reduce caloric intake without a constant sense of deprivation.
In practice, many people report a spontaneous reduction in portion sizes and a decreased attraction to food, especially in situations where overeating or impulsive eating typically occurs. This is one of the most relevant aspects of the therapy, as it directly impacts the sustainability of weight loss.
However, it is important to note that weight loss does not depend solely on the pharmacological effect. Real effectiveness is achieved when appetite reduction is combined with more stable eating habits and a healthy lifestyle, otherwise the result risks being temporary.
In the treatment of type 2 diabetes, GLP-1 drugs act through a more targeted mechanism compared to many traditional therapies. Their main action is to stimulate insulin secretion in a glucose-dependent manner, meaning only when blood sugar levels are elevated, reducing the risk of hypoglycemia when used alone.
At the same time, they help reduce the production of glucagon, the hormone produced by the pancreas that signals the liver to release glucose into the bloodstream. This dual effect helps limit both post-meal glucose spikes and elevated fasting levels, improving overall glycemic control.
One of the most relevant indicators in this context is glycated hemoglobin (HbA1c), a parameter that reflects average blood glucose levels over time. GLP-1 drugs have been shown to significantly reduce HbA1c, making them an important therapeutic option, especially in patients who struggle to achieve stable control with other treatments.1
Glycemic control is therefore not an isolated effect, but the result of a broader regulation involving multiple organs and metabolic signals.
Beyond visible effects on body weight, GLP-1 drugs act on a less immediate but more structural level: the central regulation of appetite. Their effect involves specific areas of the brain, particularly the hypothalamus, which integrates signals related to hunger and satiety.
When these receptors are activated, the brain receives an earlier and more stable fullness signal. This means that the feeling of satiety not only arrives sooner but also lasts longer, reducing the frequency and intensity of the urge to eat between meals.
Unlike approaches that rely solely on willpower or caloric restriction, this mechanism changes how the body perceives the need for food. The result is a reduction in the constant pressure of hunger, which is often one of the main obstacles in weight management.
The effectiveness of GLP-1 drugs is now well established, but in clinical practice, the most delicate issue concerns their tolerability. Side effects cannot be considered a marginal aspect, as they directly affect treatment continuity and the patient’s ability to maintain therapy over time.
The most frequent disorders affect the gastrointestinal system and include nausea, vomiting, diarrhea, constipation, and excessive fullness. These symptoms typically appear during the initial stages of treatment or after dose increases, as they are linked to how the drug alters digestion speed and satiety signals.
For this reason, therapy management involves gradual dose titration, allowing the body to adapt progressively. Even so, not all patients tolerate treatment in the same way, and in some cases, symptoms can become a real barrier to continuing therapy.
Alongside the more common effects, there are less frequent but clinically significant risks, such as acute pancreatitis or the formation of gallstones, especially in cases of rapid weight loss. These are accompanied by possible alterations in kidney function, often linked to prolonged dehydration.
A rarely explored aspect concerns the quality of weight loss. Body weight reduction may involve not only fat mass but also muscle mass, with consequences for metabolism and the ability to maintain results over time. This makes it essential to combine therapy with adequate nutritional support and targeted physical activity.
Recent clinical evidence highlights the impact of semaglutide and GLP-1 analogues on body composition. A 2024 systematic review involving over 1,500 patients showed that lean mass reduction can vary widely, from 0% up to 40% of total weight loss.2 These findings are supported by a contemporary meta-analysis, which estimates non-adipose tissue loss between 25% and 39%.3 Specifically, the STEP-1 trial indicates that about one-third of weight loss is attributable to lean mass; however, this occurs alongside a significant reduction in visceral fat and an overall improvement in metabolic efficiency.4
This is why the drug represents only part of the journey. Managing side effects, preserving lean mass, and maintaining consistent habits become essential elements in turning initial results into lasting change. It is precisely in this context that the role of dietary supplementation in GLP-1 therapy becomes relevant, as a concrete support to improve tolerability and guide the patient throughout all stages of treatment.
The use of GLP-1 drugs requires careful clinical evaluation. There are conditions in which their use is contraindicated or must be handled with particular caution, as the risks may outweigh the expected benefits.
One of the main contraindications is pregnancy, during which these drugs must not be used. Likewise, they are not recommended for patients with a history of pancreatitis, given the risk, albeit rare, of recurrence.
Another limitation concerns type 1 diabetes, for which GLP-1 receptor agonists are not indicated. Their mechanism of action is designed to support residual insulin function, a condition not present in this form of diabetes.
Beyond absolute contraindications, there are situations that require deeper evaluation, such as significant gastrointestinal conditions or states that increase the risk of dehydration. In these cases, therapy must be personalized and accompanied by close monitoring.
The use of GLP-1 drugs follows well-defined clinical criteria and cannot be interpreted as a general solution for weight loss. Their prescription is based on objective parameters and a comprehensive evaluation of the patient’s profile.
GLP-1 agonists are typically prescribed to manage type 2 diabetes when standard treatments are insufficient or cannot be used, or when the patient has kidney issues, cardiovascular diseases, or arterial conditions.
From a regulatory perspective, some GLP-1 receptor agonists have received specific approval for chronic weight management. In particular, liraglutide was approved by the FDA for this indication in December 2014, followed by semaglutide in July 2021.5 In this context, their use is part of a structured therapeutic approach rather than an aesthetic one.
A key element is patient selection and the definition of therapeutic goals. Not all individuals respond in the same way, and not all are ideal candidates for this type of treatment. Initial assessment must consider not only weight or glycemia, but also the ability to sustain the process over time.
In recent years, the development of GLP-1 analogues has led to significant progress in the treatment of obesity and type 2 diabetes. The main GLP-1 agonists such as semaglutide, liraglutide, and tirzepatide have shown meaningful clinical results. The use of GLP-1RAs (Glucagon-like peptide-1 receptor agonists) is associated with a reduction in BMI of 5 to 10 kg/m², as well as weight loss ranging from 10% to 30% compared to baseline values.6
These drugs differ in structure, duration of action, and mode of administration. Some require daily injections, others weekly, and oral formulations are also available. This variety allows for greater personalization of therapy.
Research is moving toward new formulations and therapeutic strategies aimed at improving not only effectiveness but also long-term management. Discontinuation of treatment, in fact, can lead to weight regain, especially in the absence of sustained lifestyle changes. This phenomenon, often referred to as the rebound effect, represents one of the main challenges in clinical management.
In this context, the future of therapy cannot be interpreted only in terms of new drugs to treat obesity, but as the evolution of a broader model in which pharmacological treatment is integrated with nutritional strategies and targeted support.
It is precisely within this perspective that companies like Cor.Con. International aim to improve the therapeutic pathway by developing solutions that support patients in managing side effects and maintaining long-term results. The goal is not to replace pharmacological therapy, but to make it more sustainable and more effective over time, also through supplements for metabolic system designed to support metabolic well-being.
As treatment effectiveness increases, managing the entire therapeutic pathway becomes more important. Only in this way can results be transformed into lasting change.